Bold Therapeutics' Clinical-Stage Anticancer Agent BOLD-100 Demonstrates Neuroprotective Potential when Utilized in Combination with FOLFOX for the Treatment of Advanced Gastrointestinal Cancers
VANCOUVER, BC, May 28, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company founded to develop and commercialize novel metallotherapeutics, is presenting data to support the neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for...
VANCOUVER, BC, May 28, 2026 /PRNewswire/ -- Bold Therapeutics, a clinical-stage biopharmaceutical company founded to develop and commercialize novel metallotherapeutics, is presenting data to support the neuroprotective potential of BOLD-100 when utilized in combination with FOLFOX for...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.